Value in Health

Article	Citations
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	374
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force	367
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis	72
The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results	71
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?	67
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report	64
Using Virtual Reality Exposure Therapy in Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	61
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review	60
Distributional Cost-Effectiveness Analysis Comes of Age	59
Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations	58
Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review	57
Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis	55
Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis	55
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach	53
Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set	49
Preferences for e-Mental Health Interventions in Germany: A Discrete Choice Experiment	49
Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings	48
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis	47
Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force	44
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies	42
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review	41
Do People Favor Artificial Intelligence Over Physicians? A Survey Among the General Population and Their View on Artificial Intelligence in Medicine	41
Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review	40
Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB	40
The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis	38

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials	38
Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah	35
A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health	34
Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey	32
Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report	31
Mapping EQ-5D-3L to EQ-5D-5L	31
Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease	30
Did the Integrated Urban and Rural Resident Basic Medical Insurance Improve Benefit Equity in China?	30
Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index	30
Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data	29
A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force	29
Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation	29
Economic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review	28
Methods Used to Identify, Test, and Assess Impact on Preferences of Bolt-Ons: A Systematic Review	27
Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?	27
Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective	27
Quality-Adjusted Life Expectancy Norms for the English Population	26
A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma	25
Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective	25
A Conceptual Framework for Life-Cycle Health Technology Assessment	25
Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches	25
A Comparison of 7 Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies	25
Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients	24
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs	24
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making	24
Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios	24
Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management	24
Indirect Economic Burden of Sickle Cell Disease	24
Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities	24
Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review	23
Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?	23
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force	23
Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis	23
Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study	23
New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey	22
The Roadmap for Implementing Value-Based Healthcare in European University Hospitals—Consensus Report and Recommendations	22
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19	22
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review	22
Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care	22
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility	22
Prevalence and Risk Factors of Primary Dysmenorrhea in Students: A Meta-Analysis	21
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis	21
Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB	21
The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review	20
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Develo	20
Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England	19
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life	19
Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review	19
Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis	19
Cost-Effectiveness of Propofol (Diprivan) Versus Inhalational Anesthetics to Maintain General Anesthesia in Noncardiac Surgery in the United States	19

Development and Psychometric Testing of the Caregiver Self-Efficacy in Contributing to Patient Self-Care Scale	19
The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review	19
Economic Consequences of Adult Living Kidney Donation: A Systematic Review	18
Qualitative Review on Domains of Quality of Life Important for Patients, Social Care Users, and Informal Carers to Inform the Development of the EQ-HWB	18
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications	18
A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults	18
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands	18
Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income	18
Economic Evaluation in Opioid Modeling: Systematic Review	17
Measurement Properties of the EQ-5D-Y: A Systematic Review	17
The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis	17
How Much Is a Human Life Worth? A Systematic Review	17
Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands	17
Valuation of Informal Care Provided to People Living With Dementia: A Systematic Literature Review	17
Considering Severity in Health Technology Assessment: Can We Do Better?	17
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018	17
Fulfilling the Promise of Artificial Intelligence in the Health Sector: Let’s Get Real	17
Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL	17
Caregiving-Related Work Productivity Loss Among Employed Family and Other Unpaid Caregivers of Older Adults	16
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare	16
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies	16
Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis	16
Analyzing the Pain/Discomfort and Anxiety/Depression Composite Domains and the Meaning of Discomfort in the EQ-5D: A Mixed-Methods Study	16
Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches	16
Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation	16
Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations	15
A Comparison of a Preliminary Version of the EQ-HWB Short and the 5-Level Version EQ-5D	15
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies	15
A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales	15
Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030	15
Quantifying the Effect of Public Activity Intervention Policies on COVID-19 Pandemic Containment Using Epidemiologic Data From 145 Countries	15
Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov	15
Healthcare Resource Utilization of Patients With COVID-19 Visiting US Hospitals	15
Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis	15
Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States	15
Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes	15
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%	15
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force	14
Exploration of the Reasons Why Health State Valuation Differs for Children Compared With Adults: A Mixed Methods Approach	14
A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain	14
Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study	14
Valuing the EQ Health and Wellbeing Short Using Time Trade-Off and a Discrete Choice Experiment: A Feasibility Study	14
To What Extent Do Patient Preferences Differ From General Population Preferences?	14
The Potential Cost-Effectiveness of a Machine Learning Tool That Can Prevent Untimely Intensive Care Unit Discharge	14
One-Year Temporal Changes in Long COVID Prevalence and Characteristics: A Systematic Review and Meta-Analysis	14
10 Years of End-of-Life Criteria in the United Kingdom	14
Cost-Effectiveness of an Opioid Abuse–Prevention Program Using the Narcotics Information Management System in South Korea	14
Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment	13
Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions	13
The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study	13
An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis	13
Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States	13
The Garbage Class Mixed Logit Model: Accounting for Low-Quality Response Patterns in Discrete Choice Experiments	13
A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample	13
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force	13
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues	13
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis	13
What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks	13
Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review	13
Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey	13
Quantifying Value of Hope	13
Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France	13
Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies	13
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England	13
A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder Deliberative Process in Latin America	13
Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration	13
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study	13
Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands	13
Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology	13
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia	13
Effectiveness of Pneumococcal Vaccines on Otitis Media in Children: A Systematic Review	13
Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer	12
Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands	12
Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017	12
A Comparison of the Cost-Effectiveness of Lifestyle Interventions in Pregnancy	12
Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire	12
Developing Criteria for Health Economic Quality Evaluation Tool	12
Cost-Effectiveness of Food Allergy Interventions in Children: A Systematic Review of Economic Evaluations	12
How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report	12
Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany	12

Drug Prices and Value of Oncology Drugs in Italy	12
The Sensitivity and Specificity of Repeated and Dominant Choice Tasks in Discrete Choice Experiments	12
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations	12
Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology–Based Tool to Support and Review Registries	12
Public Preferences for Policies to Promote COVID-19 Vaccination Uptake: A Discrete Choice Experiment in The Netherlands	12
A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients With COVID-19	11
Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis	11
Measuring Financial Burden in Families of Children Living With Life-Limiting Conditions: A Scoping Review of Cost Indicators and Outcome Measures	11
An Exploratory Analysis of the “Was It Worth It?” Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment	11
Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment–Based Valuation Studies Affect Health Preferences?	11
Patient Self-Care and Caregiver Contribution to Patient Self-Care of Chronic Conditions: What Is Dyadic and What It Is Not	11
Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process	11
Reported Challenges in Health Technology Assessment of Complex Health Technologies	11
Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products	11
Programmatic Costs of the Telehealth Ostomy Self-Management Training: An Application of Time-Driven Activity-Based Costing	11
What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model	11
Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges	11
A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments	11
Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda	11
A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole	11
Modeling the Recovery of Elective Waiting Lists Following COVID-19: Scenario Projections for England	11
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?	11
Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic	11
Burden of Providing Informal Care for Patients with Atrial Fibrillation	11
Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice	11
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis	11
A Real-World Comparison of 1-Year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 Versus CoreValve Versus Evolut R	11
Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States	11
Nature and Predictors of Response Changes in Modified-Delphi Panels	10
Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study	10
Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies	10
Influence of Shared Decision Making on Decisional Conflict and Regret in Postpartum Mother–Infant Care: A Randomized Controlled Trial	10
Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products	10
Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis	10
PNS100 The New Reimbursement Route for Digital Health Applications (DIGA) in Germany: Critical Appraisal and First Evaluation of the Possible Effect on the German Healthcare System	10
Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany	10
A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients	10
Late Pregnancy Ultrasound to Screen for and Manage Potential Birth Complications in Nulliparous Women: A Cost-Effectiveness and Value of Information Analysis	10
Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials	10
Financing and Reimbursement of Approved Advanced Therapies in Several European Countries	10
Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany	10
Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods	10
Defining a Core Data Set for the Economic Evaluation of Precision Oncology	10
Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma	10
Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease	10
Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories	10
Generic Health-Related Quality of Life Utility Measure for Preschool Children (Health Utilities Preschool): Design, Development, and Properties	10
Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report	10
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer	10
Adherence to Clinical Practice Guideline Recommendations on Low-Value Injury Care: A Multicenter Retrospective Cohort Study	10
Stepwise Design and Evaluation of a Values-Oriented Ambient Intelligence Healthcare Monitoring Platform	10
The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis	10
PNS21 From Disease Burden to Healthcare Cost: Highlighting the Health Economics Aspects of the COVID-19 Pandemic	10
Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019	9
PNS263 Pandemics and Access to Care: Use of Real-World DATA to Examine the IMPACT of COVID-19 on Pharmacy Visits in JAPAN	9
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial	9
Supporting Informal Caregivers of People With Dementia in Cost-Effective Ways: A Systematic Review and Meta-Analysis	9
Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures	9
Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review	9
The CAPACITI Decision-Support Tool for National Immunization Programs	9
Valuing Child Health Isn’t Child’s Play	9
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib	9
Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate	9
Economic Evaluation of New Models of Care: Does the Decision Change Between Cost-Utility Analysis and Multi-Criteria Decision Analysis?	9
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study	9
The Impact of Banning Electronic Nicotine Delivery Systems on Combustible Cigarette Sales: Evidence From US State-Level Policies	9
HTA13 Updating Nice Evidence Standards Framework for the Effectiveness and Economic Impact of Digital Health Technologies	9
Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs	9
Where Are Populations Aging Better? A Global Comparison of Healthy Aging Across Organization for Economic Cooperation and Development Countries	9
Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study	9
Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents	9
Disparities in Access to Radiation Therapy by Race and Ethnicity in the United States With Focus on American Indian/Alaska Native People	9
Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults	9
Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma	9
Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs	8
PIN68 COVID-19 Simulator: An Interactive Tool to Inform COVID-19 Intervention Policy Decisions in the United States	8
Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? A Retrospective Analysis of Switzerland 2015-2020	8
Evidence of Stability in Patient-Reported Global Health During the COVID-19 Pandemic	8
How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?	8
Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma	8
Medicaid Expansion’s Impact on Emergency Department Use by State and Payer	8
Predicting Potential Prevention Effects on Hospital Burden of Nosocomial Infections: A Multistate Modeling Approach	8
A Review of Current Approaches to Defining and Valuing Innovation in Health Technology Assessment	8
Evaluating the Health-Related Quality of Life of the Rare Disease Population in Hong Kong Using EQ-5D 3-Level	8
Cost-Utility Analysis of a Complex Intervention to Reduce School-Based Bullying and Aggression: An Analysis of the Inclusive RCT	8
An Investigation of Age-Related Differential Item Functioning in the EQ-5D-5L Using Item Response Theory and Logistic Regression	8
Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands	8
Consultations for Influenza-Like Illness in Primary Care in The Netherlands: A Regression Approach	8
Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products	8
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia	8
Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?	8
Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison	8
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Ca	8
Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis	8
The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies	8